IOVA Shareholder Alert: Robbins LLP Informs Investors of the Iovance Biotherapeutics, Inc. Class Action Lawsuit

Core Points - A class action has been filed against Iovance Biotherapeutics, Inc. for allegedly misleading investors regarding its business prospects during the class period from May 9, 2024, to May 8, 2025 [1][2] - The complaint highlights several issues, including delays in treatment timelines at new Authorized Treatment Centers (ATCs), ineffective patient identification and selection, and the resulting higher costs and lower revenue [2] - Iovance reported a significant decline in quarterly product revenue, dropping from $73.7 million to$49.3 million, and revised its full-year revenue guidance down by over 40% [3] Company Performance - Iovance's first quarter 2025 financial results showed total product revenue of $49.3 million, a decrease of approximately 33$450 million - $475 million to$250 million - $300 million, indicating a substantial downward revision [3] Legal Proceedings - Shareholders interested in participating in the class action must file their papers by July 14, 2025, to serve as lead plaintiff [4] - The class action allows shareholders to recover losses without needing to actively participate in the case [4]